Copenhagen-born CathVision has raised $7.2 million from its existing investors. The startup’s EP technology provides clean electrical activation signals and enables electrophysiologists to diagnose and treat complex atrial arrhythmias with low-noise high fidelity cardiac electrograms, which conventional EP recording systems are unable to do so. Danish startup will use the capital to improve AI-powered analytic modules and further its commercialization strategy for the ECGenius™ System.
“Our investors have witnessed the evolution of our company and technology in recent years,” said Mads Matthiesen, CEO, CathVision. “Reinvesting in the company demonstrates confidence in our innovation, ongoing development, and ability to advance adoption of the ECGenius System throughout the United States as we focus on empowering physicians to diagnose, characterize, and treat cardiac arrhythmias more effectively. We are expanding our sales team, building our U.S. presence, and furthering the development of analytic modules.”
CathVision was founded in 2013 to cure cardiac arrhythmia by empowering healthcare professionals with cutting-edge technology. The ECGenius System includes a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms. The technology represents a crucial progression in the quality of cardiac signal acquisition, the accuracy of electrogram interpretation, and the advancement of therapy support to help electrophysiologists improve the overall diagnosis and treatment of complex atrial arrhythmias, including atrial fibrillation (AF), which increases the risk of stroke and heart failure.
“Cardiac ablation is one of the fastest growing markets in healthcare; treatment efficiency and efficacy must improve for physicians to deliver the best possible care for patients with atrial fibrillation and other cardiac arrhythmias,” said Matthieu Bocquet, Founding Partner, Lumine Capital. “CathVision’s modern and precise EP recording technology brings more clarity to physicians by delivering clear signals that can be accurately interpreted. This is a necessary step to improve treatment outcomes.”
CathVision has been awarded a competitive EU grant of €2.2M for the clinical development of its software and clinical decision support platform. Earlier, the startup received investment from Vaekstfonden and Danish innovation incubator BOREAN Innovation.